Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-302-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral studies have been performed with potassium tetraborate, disodium tetraborate, sodium tetraborate penthydrate and sodium tetraborate decahydrate and the UVCB test item. Acute dermal and inhalation studies have been performed with disodium tetraborate pentahydrate and disodium tetraborate decahydrate. Experimental data showed low acute toxicity to dipotassium tetraborate.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- No data
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Guideline study with acceptable restrictions.
- Qualifier:
- according to guideline
- Guideline:
- other: Regulations for the Enforcement of the Federal Hazardous Substances Act (revised Federal Register) 1964.
- Deviations:
- not specified
- GLP compliance:
- no
- Remarks:
- Study pre-dates GLP
- Test type:
- standard acute method
- Species:
- rat
- Strain:
- not specified
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Industries
- Weight at study initiation: 208 to 262 g
- Fasting period before study: 18 h
- Housing: In groups in wire mesh cages suspended above the droppings.
- Diet: Ad libitum
- Water: Ad libitum - Route of administration:
- oral: gavage
- Vehicle:
- not specified
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 50 % w/v - Doses:
- 0.464, 1.00, 2.15, 4.64 and 10.0 g/kg bw.
- No. of animals per sex per dose:
- Five
- Control animals:
- not specified
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Frequently during the day of dosing; at least once daily thereafter.
- Necropsy of survivors performed: Yes
- Other examinations performed: Clinical signs; body weight at the end of the study - Statistics:
- Statistical analysis of the mortality data was by the moving average method.
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 3.69 other: g/kg
- Based on:
- test mat.
- 95% CL:
- 2.71 - 5.01
- Mortality:
- See table.
- Clinical signs:
- other: All of the rats at the 0.464 and 1.00 g/kg levels exhibited normal appearance and behaviour on the day of dosage and throughout the observation period. Two rats at the 2.15 g/kg level exhibited mucoid diarrhoea on the day of dosage. On the first day pos
- Gross pathology:
- Gross necropsies performed on all the rats that died revealed external evidence of diarrhoea in all of the rats and excessive salivation stains in three rats. Internally the majority of the rats showed congestion of the lungs, adrenals and kidneys; diffuse irritation of the entire gastrointestinal tract which contained a fluid resembling the sample,; irritation of the peritoneal walls; and evidence of autolytic alterations. The liver of one rat was pale.
Necropsies performed at termination revealed no significant gross pathological alterations. - Interpretation of results:
- toxic
- Remarks:
- Migrated information Criteria used for interpretation of results: other: Regulations for the Enforcememnt of the Federal Hazardous Substances Act, 1964.
- Conclusions:
- The acute oral toxicity of potassium tetraborate granular was evaluated in accordance with the techniques specified in the Regulations for the enforcement of the federal hazardous Substances Act (Revised Federal Register, 1964). The acute oral LD50 of the test substance in male albino rats was found to be 3.69 g/kg with 95 % confidence limits of 2.71 - 5.01 g/kg bw.
Based on these results, potassium tetraborate granular was classified as toxic by ingestion under the above cited regulations. - Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- No data
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- not specified
- Remarks:
- This study was carried out to confirm a previous study, that indicated the LD50 was > 2000 mg/kg, where 40 % of the male rats died at 2000 mg/kg. Doses were selected on the basis of clinical observations and time of onset of signs or death previously.
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- other: Crl:CD.BR
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK.
- Age at study initiation: 5-8 weeks old
- Weight at study initiation: 143-198 g - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Amount of vehicle: Adjusted to weight of animal
MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg - Doses:
- 1600; 2500 mg/kg bw
- No. of animals per sex per dose:
- Five males per dose.
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Necropsy of survivors performed: Yes
- Other examinations performed: Clinical signs - Statistics:
- No data
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- > 2 500 mg/kg bw
- Mortality:
- None
- Clinical signs:
- other: No deaths occurred. No effects at 1600 mg/kg. At 2500 mg/kg, piloerection observed in one animal that recovered by day 2. No other adverse effects were observed.
- Gross pathology:
- No data
- Other findings:
- No data
- Interpretation of results:
- other: No data
- Remarks:
- Criteria used for interpretation of results: other: No data
- Conclusions:
- The LD50 for male rats administered the test substance by oral gavage was > 2500 mg/kg bw.
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1982-11-15 to 1982-12-08
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Comparable to guideline study with acceptable restrictions Deviations from the guideline OECD 401(1981) - the purity and stability of the test item were missing in the study report -the time interval of clinical observation was not stated - information on the individual body weight of the animals at weekly intervals and at death/sacrifice was missing in the report. Also, information on body weight changes were missing. - necropsy findings of deceased animals were described. It was not clear if sacrificed animals were also macroscopically examined. - number of animals showing clinical signs were not given in the report.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- adopted 1981-05-12
- Deviations:
- yes
- Remarks:
- please refer to "Rationale for reliability incl. deficiencies" above
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Specific details on test material used for the study:
- The substance was initially pre-registered as EC 286-925-2 and this was the information reported in the analytical reports. Only after REACH SID refinements, the substance was correctly identified as an UVCB and required a refined EC entry. For this reason, the existing EC 286-925-2&name identifiers are reported in the testing material & in the testing robust study summaries
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Zentralinstitut für Versuchstierzucht, Hannover
- Age at study initiation: males: 54-64 days ; females: 53-63 days
- Weight at study initiation: males: 0.127-0.169 kg ; females: 140-0.187 kg
- Fasting period before study: diet withdrawal 16 hours before start of the study
- Housing: caging: Macrolon cages type II; number of animals per cage: 1; bedding: Softwood granulate type 9 ALTROMIN®
- Diet: Standard test animal diet ALTROMIN®
- Water (ad libitum): water
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 21°C±2°C
- Relative humidity: 50-60%
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- DOSE INTERVAL: in decimal geometric progression
FACTOR: 1.47; 2.15
DOSE VOLUME APPLIED: 2.15 - Doses:
- males: 464, 681, 1000 and 1470 mg/kg
females: 464, 681, 1000 and 2150 mg/kg - No. of animals per sex per dose:
- 464 mg/kg: 5 males / 5 females
681 mg/kg: 5 males / 10 females
1000 mg/kg: 10 males / 10 females
1470 mg/kg: 5 males
2150 mg/kg: 5 females - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days after administration
- Examinations performed: clinical signs, mortality and gross pathology - Statistics:
- Calculation of the LD 50 (probit analysis)*
*References:
- BLISS, C J., The Statistics of Bloassay, Academic Press, New York, 1962
- FINNEY, D.J., Probit Analysis, 2nd Ed., Cambridge Univ. Press, Cambridge 1952
- WEBER, E., Grundriß d. bid. Statistik, G. Fischer-Verlag, Stuttgart, 7. Auflage, 1972 - Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 608 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 456 - 813
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 875 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 685 - 1 116
- Mortality:
- 464 mg/kg: 0/5 males; 0/5 females
681 mg/kg: 1/5 males; 7/10 females
1000 mg/kg: 6/10 males; 8/10 females
1470 mg/kg: 5/5 males
2150 mg/kg: 5/5 females
First deaths occurred already 1 hour after administration of the test product. The time of survival of the deceased animals ranged between this time point and a maximum of 6 days after administration. In the majority deaths occurred between 1 and 24 hours after administration. - Clinical signs:
- other: As signs of toxicity firstly slight to moderate clonic convulsions occurred. In parallel strenuous respiration, mydriasis, and piloerectlon were observed. Following the convulsions, moderate to severe tremor and subsequently decrease of muscle tone as wel
- Gross pathology:
- At necropsy of the deceased animals macroscopically mainly findings at the viscera were found. Stomach and small intestine were particularly affected. They showed redness of the mucosae, accumulation of liquid and gas. Partly the stomach adhered to parts of the small intestine and the adjacent viscera.
- Interpretation of results:
- Toxicity Category IV
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- LD50 (male rats): 875 mg/kg (685 - 1116)
LD50 (female rats): 608 mg/kg (456 - 813)
According to the EC-Commission directive 67/548/EEC and its subsequent amendments, the test substance is classified as harmful if swallowed.
According to the EC-Regulation 1272/2008 and subsequent regulations, the test item is classified as Category 4.
Referenceopen allclose all
Mortality during the 14 -day observation period; values are number of animals dead/number of animals tested:
Dose g/kg |
Time of death |
|||||||||
Hours |
Days |
|||||||||
1 |
2 |
4 |
24 |
2 |
3 |
4 |
5 |
6 |
7-14 |
|
0.464 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
1.00 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
2.15 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
0/5 |
4.64 |
0/5 |
0/5 |
0/5 |
3/5 |
4/5 |
4/5 |
4/5 |
4/5 |
4/5 |
4/5 |
10.0 |
0/5 |
1/5 |
2/5 |
5/5 |
- |
- |
- |
- |
- |
- |
LD50, g/kg |
3.69; 95 % confidence limits 2.71- 5.01 g/kg |
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 608 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- No data
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study with acceptable restrictions.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Deviations:
- yes
- Remarks:
- The report lacks detail. Since the data is in line with other data on sodium borates, further testing is not warranted in the interests of animal welfare.
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Hilltop Lab Animals, Scottdale, PS.
- Age at study initiation: Young adults
- Weight at study initiation: Males 253- 278 g; females 218-245 g - Route of administration:
- inhalation: dust
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: unchanged (no vehicle)
- Details on inhalation exposure:
- MMAD: 3.1 µm + GSD .971 µm.
Top dose: ~ 2 mg/L was the highest that was obtainable under the conditions of the test.
Analytical concentration: 2040 + 160 mg/m³. - Analytical verification of test atmosphere concentrations:
- not specified
- Duration of exposure:
- 4 h
- Concentrations:
- 2040 + 160 mg/m³
- No. of animals per sex per dose:
- Five/sex/dose.
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days.
- Other examinations performed: Clinical signs, pathology. - Statistics:
- No data - Limit test
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 2.04 mg/L air (nominal)
- Exp. duration:
- 4 h
- Remarks on result:
- other: No lethal effect at limit dose.
- Mortality:
- None
- Clinical signs:
- other: Animal observations were limited due to the accumulation of test material on the walls of the exposure chamber. During the first hour of exposure, ocular discharge, hypoactivity and haunched posture were noted. Ocular discharge and a few animals exhibited
- Body weight:
- No data
- Gross pathology:
- No specific findings.
- Other findings:
- No data
- Interpretation of results:
- other: Not specified
- Remarks:
- Criteria used for interpretation of results: not specified
- Conclusions:
- Acute inhalation toxicity limit on disodium tetraborate pentahydrate gave a LC50 > 2.04 mg/L (2g/m3).
Reference
Endpoint conclusion
- Dose descriptor:
- discriminating conc.
- Value:
- 2 030 mg/m³ air
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- No data
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Meets generally accepted scientific standards with acceptable restrictions.
- Qualifier:
- according to guideline
- Guideline:
- other: This study was carried out to comply with US EPA-FIFRA guidelines at the time and carried out by the US Food and Drug Laboratories to GLP.
- Deviations:
- not specified
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: LaCrosse Industries Inc., Schenectady , New York.
- Weight at study initiation: Males: 2.19 +/- 0.27kg; females: 2.29 +/- 0.28kg - Type of coverage:
- occlusive
- Vehicle:
- not specified
- Details on dermal exposure:
- TEST SITE
- Area of exposure: Area not specified. The back of each rabbit was clipped free of fur prior to treatment.
- Type of wrap if used: Not specified
REMOVAL OF TEST SUBSTANCE
- Washing: Moist towel
- Time after start of exposure: 24 h
TEST MATERIAL
- Amount applied: Dosage to 2 g/kg bw - Duration of exposure:
- 24 h
- Doses:
- Dosage to 2 g/kg bw
- No. of animals per sex per dose:
- Five/sex/dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Other examinations performed: Clinical signs, pathlogy - Statistics:
- Not relevant – Limit test.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Mortality:
- None
- Clinical signs:
- other: Clinical changes included anorexia and decreased activity in four rabbits, diarrhoea and soft stools in 3 rabbits and nasal discharge in three rabbits.
- Gross pathology:
- The only finding in one rabbit was abdominal cavity filled with fluid.
- Other findings:
- No data
- Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: not specified
- Conclusions:
- Acute dermal limit study carried out to comply with US EPA-FIFRA guidelines at the time and carried out by the US Food and Drug Laboratories to GLP. The LD50 was > 2000 mg/kg bw indicating no acute dermal toxicity.
Reference
Endpoint conclusion
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Additional information
LD50 values of >2000 mg/kg and 608 mg/kg were recorded for the oral route for potassium tetraborate and the UVCB test item respectively; >2000 mg/kg for the dermal route for sodium tetraborate pentahydrate and disodium tetraborate decahydrate. An LC50 value > 2 mg/L was recorded for the acute inhalation studies with disodium tetraborate decahydrate and disodium tetraborate pentahydrate. The inhalation figure represents the highest attainable concentration.
One acute oral toxicity study was conducted on potassium tetraborate in rats. The acute oral LD50 of the test substance in male albino rats was found to be 3.69 g/kg with 95 % confidence limits of 2.71 - 5.01 g/kg bw. (Shipp & Young 1975).
Potassium tetraborate is of low acute toxicity. Although some of the acute oral studies were not of modern standards and were performed prior to the introduction of GLP, they are reproducible across a number of studies and species and of acceptable quality. For acute dermal and acute inhalation some studies do meet the modern GLP standard.
The following acute oral data were obtained:
Potassium tetraborate: 3690 mg/kg
brazing flux: 608 mg/kg
The following acute inhalation data were obtained:
No acute inhalation studies on brazing flux have been conducted. Studies are however available for analogous substances:
Disodium Tetraborate Pentahydrate: >2040 mg (302 mg B) /m3
Disodium Tetraborate Decahydrate: >2030 mg (300 mg B) /m3
The following acute dermal data were obtained:
No acute dermal studies of dipotassium tetraborates have been conducted. Studies were conducted on an analogue substance
Sodium Tetraborate Pentahydrate: >2000 mg/kg bw (296 mg B/kg)
Assessment entity approach
"Brazing fluxes" are mixtures of boron-containing constituents (potassium(fluoro)borates), which undergo chemical exchanges (anion exchange) and condensation reactions (e.g. formation of oligoborates, polyborates) upon mixing and further manufacturing. This results in a complex mixture of potassium borates, which cannot be fully chemically characterised for substance identity. Thus, according to the definition under REACH, such brazing fluxes must be described as a UVCB substance.
Data specifically on the UVCB substance to be registered ("reaction product of mixed inorganic base and acid resulting in complex boron, potassium and fluoride constituents") are not available. An assessment entity approach is followed based on the transformation products of this UVCB uppon dissolution in aqueous media. The substance is highly soluble and forms complex boron, potassium and fluoride constituents. The quantitatively predominant transformation productof this UVCB is represented by boric acid, which is assumed to be the determinant of human health effects because of its classification and its toxicity. For this reason, the assessment is based on information for“borates” (including potassium borate, boric acid and other borate substances).
Based on the information provided below, it may safely be assumed that under physiological conditions the chemical speciation of most of the unknown potassium boron compounds corresponds to boric acid. Thus, from a chemical point of view, there is no reason to assume that brazing fluxes would behave differently than boric acid and/or borates under physiological conditions.
The basis of this assessment entity approach is further justified by the following reasoning:
In aqueous solutions at physiological and acidic pH, low concentrations of simple inorganic borates such as boric acid B(OH)3, potassium pentaborate (K2B10O16*8H2O), potassium tetraborate (K2B4O7*4H2O), disodium tetraborate decahydrate (Na2B4O7.10H2O; borax), disodium tetraborate pentahydrate (Na2B4O7*5H2O; borax pentahydrate), boric oxide (B2O3) and disodium octaborate tetrahydrate (Na2B8O13*4H2O) will predominantly exist as undissociated boric acid. Above pH 9 the metaborate anion (B(OH)4-) becomes the main species in solution (WHO, 1998). This leads to the conclusion that the main species in the plasma of mammals and in the environment is undissociated boric acid. Since other borates dissociate to form boric acid in aqueous solutions, they too can be considered to exist as undissociated boric acid under the same conditions.
For comparative purposes, exposures to borates are often expressed in terms of boron (B) equivalents based on the fraction of boron in the source substance on a molecular weight basis. Some studies express dose in terms of B, whereas other studies express the dose in units of boric acid. Since the systemic effects and some of the local effects can be traced back to boric acid, results from one substance can be transferred to also evaluate the another substance on the basis of boron equivalents. Therefore data obtained from studies with these borates can read across in the human health assessment for each individual substance. Conversion factors are given in the table under CSR section 5.1.3, which corresponds to IUCLID section 7.1 (toxicokinetics, metabolism and distribution endpoint summary). Reference:
WHO. Guidelines for drinking-water quality, Addendum to Volume 1, 1998
Justification for classification or non-classification
Acute oral toxicity
Reference Zechel (1983) will be used as key study for acute oral toxicity, and also for classification. The LD50 for brazing flux was determined to be 608 mg/kg bw.
According to the criteria specified by Directive 67/548/EEC and subsequent regulations, the brazing flux test item shall be classified as acute toxic via the oral route (harmful if swallowed, Xn, R22). According to the EC Regulation No. 1272/2008 and subsequent regulations, the test item shall be classified as acute toxic via the oral route (acute tox. 4, H302).
Acute inhalation or dermal toxicity studies with brazing flux are not available, which is why data for the substance dipotassium tetraborate are used in an assessment entity approach. This substance is not classified either for the dermal or the inhalation route, as the LD50/LC50 values exceed the limit for classification.Therefore, according to Directive 67/548/EEC and subsequent regulations as well as EC Regulation No. 1272/2008 and subsequent regulations, classification of the test item for acute dermal or inhalation toxicity is not required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.